Allogene Therapeutics ALLO Accrued and other current liabilities
Accrued and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept allo:AccruedAndOtherLiabilitiesCurrent.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's accrued and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's accrued and other current liabilities?
- Allogene Therapeutics (ALLO) reported accrued and other current liabilities of $23.4M in Q1 2026.
- How has Allogene Therapeutics's accrued and other current liabilities changed year-over-year?
- Allogene Therapeutics's accrued and other current liabilities decreased by 6.3% year-over-year, from $24.96M to $23.4M.
- What is the long-term trend for Allogene Therapeutics's accrued and other current liabilities?
- Over 5 years (2020 to 2025), Allogene Therapeutics's accrued and other current liabilities has grown at a -8.9% compound annual growth rate (CAGR), from $44.94M to $28.24M.
- What does accrued and other current liabilities mean?
- This line item aggregates short-term financial obligations that have been incurred but not yet invoiced or paid, such as accrued compensation, professional fees, or clinical research expenses. It serves as a measure of the company's near-term operational liabilities that are expected to be settled within the next fiscal year. Tracking this balance provides insight into the company's short-term cash outflow requirements and the timing of its operational spending.